夜雨聆风
视 频 回 放
陈有海
New Cancer Immunotherapy and Al-Driven Drug Development
Immune checkpoint drugs targeting effector T lymphocytes (such as PD-1 antibody therapies) have revolutionized cancer treatment. However, most tumor patients show limited responses to these drugs. The primary reason lies in the immunosuppressive tumor microenvironment, where immune-suppressive cells (such as myeloid-derived suppressor cells and regulatory T cells) significantly diminish the efficacy of immune checkpoint inhibitors. Thus, there is an urgent need to develop novel immune checkpoint drugs targeting these immunosuppressive cells. Our team's recent research has demonstrated that the immune regulatory proteins TIPE2 and c-Rel can effectively promote tumor growth in mice by controlling the development or function of immunosuppressive cells. Here, we will discuss the molecular mechanisms of TIPE2 and c-Rel as novel immune checkpoints, as well as the latest advances in leveraging Al-driven technologies to develop innovative immune checkpoint drugs targeting immunosuppressive cells.
END
扫码关注我们吧~
